Cisco Options Spot-On: On January 23rd, 96,652 Contracts Were Traded, With 821.38K Open Interest
Wall Street Today: S&P 500 Closes at Record, Trump Keeps Appearing on TV
Cisco Stock Hits 52-week High at $61.76 Amid Robust Growth
Live Stock News: Market Waiting to See if the President Says Something Exciting Today
BofA Securities Maintains Cisco(CSCO.US) With Buy Rating
Cisco Systems (CSCO) Receives a Buy From Bank of America Securities
Trump's "Gateway to the Stars" plan triggers a shift in the AI landscape, and changes in the relationship between Microsoft and OpenAI?
① In the Stargate AI project, OpenAI, SoftBank, and Oracle jointly invested, while Microsoft, NVIDIA, and Arm are only technical partners; ② On Tuesday, Microsoft announced a modification to its exclusive computing power supply agreement with OpenAI, further fueling market speculation; ③ Insiders revealed that after upheaval in OpenAI's upper management, Microsoft was unwilling to invest large sums and that relinquishing exclusive rights was actually beneficial.
Cisco Systems (CSCO) Beats Stock Market Upswing: What Investors Need to Know
Here's Why Cisco Systems, Inc. (CSCO) Is Among the Highest Yielding Dividend Stocks In the Dow
Cisco Options Spot-On: On January 22nd, 90,687 Contracts Were Traded, With 769.97K Open Interest
Wall Street Today: Does Anyone Have the Cash for Stargates
It's the Year of Enterprise AI With AI Agents, Cisco CEO Says
Live Stock: Stargate Rivals the Scale of the Manhattan Project, Musk Said it's a Pipe Dream
Cisco CEO Says Trump Must Prioritize Preserving Tax Cuts
Companies Eager to Get AI Right, Cisco's Chuck Robbins Says -- Market Talk
US Morning News Call | Trump Announces $500B 'Stargate' AI Venture
Haisco Pharmaceutical Group (002653.SZ): Received the clinical trial approval notice for the new indication of the Innovative Drugs HSK44459 tablets.
Gelonghui, January 22 - Haisco Pharmaceutical Group (002653.SZ) announced that the company (hereinafter referred to as 'the company') has recently received the 'Drug Clinical Trial Approval Notification' from the National Medical Products Administration for HSK44459 tablets. HSK44459 tablets are a brand new medication independently developed by the company with independent intellectual property rights for the treatment of Behçet's disease. Preclinical research results indicate that this product has a clear target, definitive efficacy, and good safety, making it a small molecule drug with significant development potential. The benefit/risk ratio for clinical application is high, and it has broad prospects for clinical applications, promising to become an effective treatment for Behçet's disease.
Wall Street Today: AI Domestic Investment News on the Way
Live Stock News: Market Climbs, Crypto Falls, Big Tech is Here and Trump Starts Signing Orders
Intelligent Transportation System Market Skyrockets to $66.35 Billion by 2031 Dominated by Tech Giants - Hitachi, Siemens, DENSO and Cisco Systems, Inc. | The Insight Partners